Kite Pharma Inc. (KITE) announced after the bell Monday that pre-planned interim analysis of ZUMA-1 for KTE-C19, in patients with chemorefractory diffuse large B-cell lymphoma, met the primary endpoint.
from RTT - Before the Bell http://ift.tt/2cVaOuu
via IFTTT
No comments:
Post a Comment